Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)

Más betegség

• Patients with a history of clinically significant alcohol or drug abuse.

Laborértékek

• Patients with creatinine clearance (CCr) less than 15 ml/min.

Egyéb

• Patients with moderate to severe mitral stenosis.
• Patients who have undergone mechanical valve replacement
• Patients whom the investigator deems legally or mentally unsuitable for participation in the clinical trial, or those who do not consent to participate in the study.

• Male and female patients aged 19 years or older with chronic atrial fibrillation, accompanied by at least one of the following conditions:
  • ① Heart failure
  • ② 2. Myocardial infarction (more than 3 months post-event)
  • ③ 3. Angina (if PCI was performed, more than 3 months post-procedure)
  • ④ 4. Hypertension
  • ⑤ 5. Diabetes mellitus
• Patients who started taking Factor Xa inhibitors (Apixaban, Rivaroxaban) within the last 12 months and have echocardiographic images taken within 3 months of that time, which are available for analysis.
• Patients who are starting treatment with Factor Xa inhibitors. (Apixaban, Rivaroxaban)
• Individuals who have voluntarily provided written consent to participate in this clinical trial.